DOCSLIB.ORG

The Truth About Drug Fever Committee Met May 17, 2011

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Truth About Drug Fever Committee Met May 17, 2011 Volume 25, Number 6 June 2011 Drugs & Therapy B N U N L N L N E N T N I N N ADVERSE DRUG REACTIONS FORMULARY UPDATE The Pharmacy and Therapeutics The truth about drug fever Committee met May 17, 2011. 4 products were added in the Formu- t is estimated that about 3–7% of antimicrobials (median 6 days). Cardiac lary; 2 were deleted and designated I febrile episodes are attributed to drug and central nervous system medica- nonformulary and not available. 1 reactions; however, the true incidence is tions can induce fever at a much slower interchange was approved, while 3 unknown due to underreporting and fre- interval, median of 10 and 16 days after criteria for uses were changed. quent misdiagnosis.1 In the hospitalized initiation, respectively. patient, the most common presentation Fever patterns may present as a for drug fever is a patient with a resolv- continuous fever (temperature does not ing infection, on antimicrobial therapy, vary), remittent fever (where tempera- ◆ ADDED and after initial defervescence. Fever in tures vary, but are consistently elevat- Acetaminophen IV this patient can result in the over-utili- ed), intermittent fever (with normal (Ofirmev® by Cadence zation of antimicrobials and the addition temperatures in between), or the most Pharmaceuticals)* of agents to treat an infection that is not common: hectic fever (combination of 4 *Restricted present. This could potentially cause remittent and intermittent). Degree more adverse effects and further contrib- of pyrexia tends to range from 38.8°C Carglumic Acid ute to antimicrobial resistance. (102°F) to 40°C (104°F) but has been ® (Carbaglu by Orphan Europe) One study evaluating 51 episodes reported as high as 42.8°C (109°F). Mannitol Bronchial Challenge of drug fever in 2 Dallas hospitals from Clinically, patients with drug fever Test Kit (Aridol® by Pharmaxis) 1959 to 1986 found that episodes of drug look “inappropriately well” and are fever resulted in a mean prolongation of frequently unaware they are febrile. One Tobramycin-Dexamethasone hospital stay of 8.7 days, an average in- of the most important clues to detection Ophthalmic Suspension crease of 5 blood cultures, 2.85 more ra- of drug fever is a relative bradycardia (Tobradex® by Alcon) diologic studies, and 0.53 more courses where the heart rate does not increase of antibiotics.2 While no study evaluating to the extent that would be expected ◆ DELETED another large group of patients has been given the temperature elevation. In gen- Dextran 70 (Generic)† performed since, procedures for ruling eral, a temperature greater than 39°C out infectious and other causes of fevers should elicit a heart rate greater than Polysaccharide Iron Complex have not changed significantly and likely 110 beats per minute (assuming the pa- Liquid (Generic)† still reflect these findings. tient is not on a beta-blocker and has no †Nonformulary and not available Drug fever is difficult to diagnose conduction abnormalities).4 Findings of because it is a diagnosis of exclusion.1,3 leukocytosis, with or without a left shift, ◆ INTERCHANGES The febrile response should coincide peripheral eosinophilia, and erythrocyte Digibind® for Digifab®‡ temporally with the administration of a sedimentation rate of greater than 100 new drug and occur in the absence of mm/hour complicate the diagnosis of ® ‡Once Digibind supplies are underlying conditions that could con- drug fever and warrant further investi- exhausted, it will be interchanged 3 to Digifab® tribute to the cause. Practitioners should gation of infection. always have drug fever on their differen- In 18-29% of patients with drug fever, ◆ CRITERIA-FOR-USE CHANGES tial, especially if the patient is receiving cutaneous manifestations of hypersensi- an agent that is frequently implicated tivity are also present and allow for eas- Epoprostenol with fever. These agents include anti- ier identification of a medication as the ® ® (Flolan and Veletri )* biotics (especially beta-lactams and source of fever.3 Fever is most commonly *Restricted: Must use EPIC order set sulfonamides), antineoplastics, anti- caused by hypersensitivity to a drug and convulsants (especially phenytoin and may precede more overt clinical mani- Nicardipine IV (Cardene® IV)* carbamazepine), antiarrhythmics (mainly festations of a drug reaction. Drug fever *Restricted use expanded to select quinidine and procainamide), and other due to hypersensitivity may develop adult uses cardiac medications (methyldopa).1 over several days to weeks;however, Treprostinil IV (Remodulin®)* Drug fever can occur at any point dur- if the drug is discontinued and rein- *Restricted: Must use EPIC order set ing a course of therapy with significant troduced days, months, or years later, variation among patients.3,4 The median fever will likely develop within hours of time to presentation of fever is 7 to 10 re-administration. days, with a faster onset with antineo- (continued on page 4) (continued on next page) plastic agents (median 0.5 days) and ◆ CRITERIA-FOR-USE CHANGES (cont.) Formulary update, from page 1 or enteral dosage form when other medi- consensus is that the mannitol test is Intravenous (IV) acetaminophen is cations are being given orally or enterally. a more specific but less sensitive test an antipyretic and analgesic with FDA- Rectal acetaminophen is an alternative to than the methacholine challenge test. labeled indications for use in adults and IV acetaminophen that should always be Many trials have examined the children (greater than 2 years old) for considered. diagnostic properties of both the management of pain and fever. Formu- Since, IV acetaminophen should be mannitol and methacholine challenge lation issues previously limited acet- used only when patients cannot take tests. One of the main limitations seen aminophen’s IV stability and its use as other oral medications, using more than 4 across all studies is the fact there is no an injectable agent. IV acetaminophen grams per day of acetaminophen should “gold-standard” definition for asthma has fewer local adverse events and not be a concern with IV acetaminophen. diagnosis to compare the challenge test similar efficacy to propacetamol, the Overdose remains a concern with oral results. Consequently, the definition intravenous prodrug of acetaminophen acetaminophen and acetaminophen for asthma diagnosis is highly variable that has been used in Europe. combinations like Percocet®, and pre- across studies. This affects overall gen- IV acetaminophen works centrally to scribers should monitor the total dose eralizability of study results since it is inhibit cyclooxygenase (COX) enzymes of acetaminophen (eg, do not exceed 4 possible that diagnoses of asthma will to disrupt prostaglandin synthesis. grams per day in adults). vary from physician to physician. Other The onset of action for analgesia and Carglumic acid is a carbamoyl phos- limitations of these trials include pos- antipyretic effects is expected to occur phatase synthetase 1 (CPS1) activator sible sampling bias and the utilization within 15 and 30 minutes, respectively, with labeled indications for the treatment of younger population samples. of the start of the infusion. Prescrib- of acute hyperammonemia due to the Although most studies indicated ers should remember, however, that it deficiency of the hepatic enzyme N-acetyl- that mannitol is a more specific test is just an intravenous dosage form of glutamate synthase (NAGS) and for main- than methacholine, 1 study found that acetaminophen and works just like oral tenance therapy of chronic hyperammo- the sensitivity and specificity for both and rectal acetaminophen. nemia due the deficiency of NAGS. NAGS mannitol and methacholine to identify IV acetaminophen is supplied as a deficiency is a rare disorder, and, there- exercise-induced bronchospasm and 100-mL, single-use vial of 10 mg/mL fore, its safety and efficacy was evaluated a clinician diagnosis of asthma were and is administered as a 15-minute in only 23 patients before it was approved equivalent. Unlike populations in other infusion. The labeled dose for adults by the FDA. Few cases of NAGS deficiency studies, the population evaluated in this and adolescents greater than 50 kg is have been reported and the overall inci- study consisted of subjects with normal 1000 mg every 6 hours or 650 mg every dence is unknown. NAGS deficiency is one FEV1, mild symptoms, and mild airway 4 hours. Children 2 to 12 years of age of several urea cycle disorders. hyperresponsiveness. Essentially, and adolescents less than 50 kg should In February, the P&T Committee these subjects did not have a confirmed receive 12.5 mg/kg every 4 hours or designated carglumic acid a high-priority diagnosis of asthma; they only had 15 mg/kg every 6 hours. There is no nonformulary drug with instructions in symptoms suggestive of asthma. This advantage for the 4-hour dosage inter- our computer systems on how to obtain population is, therefore, more analogous val, which is more expensive because it. Carglumic acid is available from Ac- to populations in which these challenge it uses more product and increases credo, and we have already purchased it tests would actually be utilized. waste. twice when a patient was admitted and The mannitol challenge test was In studies evaluating IV acetamino- could not provide their own supply. added in the Formulary as an alterna- phen’s use in adults, it was effective The original assumption for designat- tive to the methacholine challenge test. when compared to placebo for post- ing this product a high-priority nonfor- It should be used as part of a clinician’s operative analgesia. Studies show a mulary drug was that it would rarely be overall evaluation of asthma and should decrease in opioid use in the first 24 used. It is very expensive and has a short not serve as the sole criterion for diag- hours when IV acetaminophen is used. shelf life. A 5-tablet bottle costs $685 nosis or as a screening test for asthma.
Load more

Recommended publications
  • Parenteral Dilantin® (Phenytoin Sodium Injection, USP) WARNING
    1 Parenteral Dilantin (Phenytoin Sodium Injection, USP) WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH RAPID INFUSION The rate of intravenous Dilantin administration should not exceed 50 mg per minute in adults and 1-3 mg/kg/min (or 50 mg per minute, whichever is slower) in pediatric patients because of the risk of severe hypotension and cardiac arrhythmias. Careful cardiac monitoring is needed during and after administering intravenous Dilantin. Although the risk of cardiovascular toxicity increases with infusion rates above the recommended infusion rate, these events have also been reported at or below the recommended infusion rate. Reduction in rate of administration or discontinuation of dosing may be needed (see WARNINGS and DOSAGE AND ADMINISTRATION). DESCRIPTION Dilantin (phenytoin sodium injection, USP) is a ready-mixed solution of phenytoin sodium in a vehicle containing 40% propylene glycol and 10% alcohol in water for injection, adjusted to pH 12 with sodium hydroxide. Phenytoin sodium is related to the barbiturates in chemical structure, but has a five-membered ring. The chemical name is sodium 5,5-diphenyl-2, 4- imidazolidinedione represented by the following structural formula: CLINICAL PHARMACOLOGY Mechanism of Action Phenytoin is an anticonvulsant which may be useful in the treatment of generalized tonic­ clonic status epilepticus. The primary site of action appears to be the motor cortex where spread of seizure activity is inhibited. Possibly by promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of posttetanic potentiation at synapses. Loss of posttetanic potentiation prevents cortical seizure foci from detonating adjacent cortical areas.
    [Show full text]
  • Missouri Hospitalist Missouri Society
    MISSOURI HOSPITALIST MISSOURI SOCIETY HOSPITALIST Publisher: Issue 22 October 22, 2009 Division of General IM University of Missouri Hospitalist Update Columbia, Missouri Dealing with Hypertensive Urgencies Syed Ahsan, MD Editor: Robert Folzenlogen MD INTRODUCTION Patients presenting with severe hypertension can often be alarming for house officers and family members. Systolic blood pressures > 180 mm Hg, with or without a diastolic blood pressure >120, have been known to progress to hypertensive emer- Inside this issue: gencies. The majority of complications are related to end organ damage; this may include encephalopa- thy, blurred vision, chest pain, unstable angina, Hospitalist Update acute myocardial infarction and acute renal insuffi- ciency, with or without proteinuria. In the absence of these acute signs, the control of hypertensive urgency remains paramount but is not considered an emergency. Case of the Month The etiology of severe, asymptomatic hypertension is extremely important in defin- ing treatment strategies. The majority of these patients have a prolonged history of uncontrolled hypertension secondary to poor compliance or inadequate treatment From the Journals regimens. Guidelines are not entirely specific in the management of hypertensive ur- gency. ID Corner TREATMENT STRATEGY Based on the current literature, the following approach is recommended: Calendar 1. Confirm that the blood pressure is elevated. The reading should be re- peated in both upper extremities; the physician should ensure that the appropriate cuff size is used and that the readings are consistent. Comments 2. Goal for blood pressure reduction: the ideal goal is to reduce the systolic blood pressure by 20-25% and this should be done over a period of hours to days.
    [Show full text]
  • Dilantin (Phenytoin Sodium) Extended Oral Capsule Three Times Daily and the Dosage Then Adjusted to Suit Individual Requirements
    Dilantin® (Phenytoin Sodium) 100 mg Extended Oral Capsule DESCRIPTION Phenytoin sodium is an antiepileptic drug. Phenytoin sodium is related to the barbiturates in chemical structure, but has a five-membered ring. The chemical name is sodium 5,5-diphenyl-2, 4-imidazolidinedione, having the following structural formula: Each Dilantin— 100 mg Extended Oral Capsule—contains 100 mg phenytoin sodium. Also contains lactose monohydrate, NF; confectioner’s sugar, NF; talc, USP; and magnesium stearate, NF. The capsule body contains titanium dioxide, USP and gelatin, NF. The capsule cap contains FD&C red No. 28; FD&C yellow No. 6; and gelatin NF. Product in vivo performance is characterized by a slow and extended rate of absorption with peak blood concentrations expected in 4 to 12 hours as contrasted to Prompt Phenytoin Sodium Capsules, USP with a rapid rate of absorption with peak blood concentration expected in 1½ to 3 hours. CLINICAL PHARMACOLOGY Phenytoin is an antiepileptic drug which can be used in the treatment of epilepsy. The primary site of action appears to be the motor cortex where spread of seizure activity is inhibited. Possibly by promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of posttetanic potentiation at synapses. Loss of posttetanic potentiation prevents cortical seizure foci from detonating adjacent cortical areas. Phenytoin reduces the maximal activity of brain stem centers responsible for the tonic phase of tonic-clonic (grand mal) seizures. The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
    [Show full text]
  • A Review of Undulant Fever : Particularly As to Its Incidence, Origin and Source of Infection
    University of Nebraska Medical Center DigitalCommons@UNMC MD Theses Special Collections 5-1-1938 A Review of undulant fever : particularly as to its incidence, origin and source of infection Richard M. Still University of Nebraska Medical Center This manuscript is historical in nature and may not reflect current medical research and practice. Search PubMed for current research. Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses Part of the Medical Education Commons Recommended Citation Still, Richard M., "A Review of undulant fever : particularly as to its incidence, origin and source of infection" (1938). MD Theses. 706. https://digitalcommons.unmc.edu/mdtheses/706 This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. ·~· A REVIEW OF UNDULANT FEVER PARTICULARLY AS TO ITS INCIDENCE, ORIGIN AND SOURCE OF INFECTION RICHARD M. STILL SENIOR THESIS PRESENTED TO THE COLLEGE OF MEDICINE, UNIVERSITY OF NEBRASKA, OMAHA, NEBRASKA, 1958 SENIOR THESIS A REVIEW OF UNDULANT FEVER PARTICULARLY AS TO ITS;. INCIDENCE, ORIGIN .AND SOURCE OF INFECTION :trJ.:RODUCTION The motive for this paper is to review the observations, on Undul:ant Fever, of the various authors, as to the comps.rat!ve im- portance of' milk borne infection and infection by direct comtaC't.•.. The answer to this question should be :of some help in the diagnos- is ot Undulant Fever and it should also be of value where - question of the disease as an occupational entity is presented.
    [Show full text]
  • Adult Onset Still's Disease Accompanied by Acute Respiratory Distress Syndrome: a Case Report
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 12: 1817-1821, 2015 Adult onset Still's disease accompanied by acute respiratory distress syndrome: A case report XIAO-TU XI1, MAO‑JIE WANG2, RUN‑YUE HUANG2 and BANG‑HAN DING1 1Emergency Department; 2Rheumatology Department, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, Guangdong 510006, P.R. China Received July 17, 2015; Accepted May 20, 2016 DOI: 10.3892/etm.2016.3512 Abstract. Adult onset Still's disease (AOSD) is a systemic vascular permeability and a loss of aerated lung tissue (8). inflammatory disorder characterized by rash, leukocytosis, ARDS occurs in 7.2‑38.9/100,000 individuals (9,10), and has fever and arthralgia/arthritis. The most common pulmo- a mortality rate of ~40% (11). Patient mortality varies based nary manifestations associated with AOSD are pulmonary on numerous factors, including age, etiology of the lung injury infiltrates and pleural effusion. The present study describes and non‑pulmonary organ dysfunction. The most common a 40‑year‑old male with AOSD who developed fever, sore risk factors for ARDS are pneumonia, sepsis, aspiration and throat and shortness of breath. Difficulty breathing promptly trauma (11). Multiple predisposing risk factors, in addition to developed, and the patient was diagnosed with acute respira- some secondary factors such as alcohol abuse and obesity, also tory distress syndrome (ARDS). The patient did not respond increase the risk (4). In addition to patient support provided by to antibiotics, including imipenem, vancomycin, fluconazole, improving oxygen delivery to the tissues and preventing multi- moxifloxacin, penicillin, doxycycline and meropenem, but was organ system failure, early recognition and correction of the sensitive to glucocorticoid treatment, including methylpred- underlying cause is important in ARDS treatment.
    [Show full text]
  • Association of Hypertensive Status and Its Drug Treatment with Lipid and Haemostatic Factors in Middle-Aged Men: the PRIME Study
    Journal of Human Hypertension (2000) 14, 511–518 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME Study P Marques-Vidal1, M Montaye2, B Haas3, A Bingham4, A Evans5, I Juhan-Vague6, J Ferrie`res1, G Luc2, P Amouyel2, D Arveiler3, D McMaster5, JB Ruidavets1, J-M Bard2, PY Scarabin4 and P Ducimetie`re4 1INSERM U518, Faculte´ de Me´decine Purpan, Toulouse, France; 2MONICA-Lille, Institut Pasteur de Lille, Lille, France; 3MONICA-Strasbourg, Laboratoire d’Epide´miologie et de Sante´ Publique, Strasbourg, France; 4INSERM U258, Hoˆ pital Broussais, Paris, France; 5Belfast-MONICA, Department of Epidemiology, The Queen’s University of Belfast, UK; 6Laboratory of Haematology, La Timone Hospital, Marseille, France Aims: To assess the association of hypertensive status this effect remained after multivariate adjustment. Cal- and antihypertensive drug treatment with lipid and hae- cium channel blockers decreased total cholesterol and mostatic levels in middle-aged men. apoproteins A-I and B; those differences remained sig- Methods and results: Hypertensive status, antihyperten- nificant after multivariate adjustment. ACE inhibitors sive drug treatment, total and high-density lipoprotein decreased total cholesterol, triglycerides, apoprotein B (HDL) cholesterol, triglyceride, apoproteins A-I and B, and LpE:B; and this effect remained after multivariate lipoparticles LpA-I,
    [Show full text]
  • Malaria History
    This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this site. Copyright 2006, The Johns Hopkins University and David Sullivan. All rights reserved. Use of these materials permitted only in accordance with license rights granted. Materials provided “AS IS”; no representations or warranties provided. User assumes all responsibility for use, and all liability related thereto, and must independently review all materials for accuracy and efficacy. May contain materials owned by others. User is responsible for obtaining permissions for use from third parties as needed. Malariology Overview History, Lifecycle, Epidemiology, Pathology, and Control David Sullivan, MD Malaria History • 2700 BCE: The Nei Ching (Chinese Canon of Medicine) discussed malaria symptoms and the relationship between fevers and enlarged spleens. • 1550 BCE: The Ebers Papyrus mentions fevers, rigors, splenomegaly, and oil from Balantines tree as mosquito repellent. • 6th century BCE: Cuneiform tablets mention deadly malaria-like fevers affecting Mesopotamia. • Hippocrates from studies in Egypt was first to make connection between nearness of stagnant bodies of water and occurrence of fevers in local population. • Romans also associated marshes with fever and pioneered efforts to drain swamps. • Italian: “aria cattiva” = bad air; “mal aria” = bad air. • French: “paludisme” = rooted in swamp. Cure Before Etiology: Mid 17th Century - Three Theories • PC Garnham relates that following: An earthquake caused destruction in Loxa in which many cinchona trees collapsed and fell into small lake or pond and water became very bitter as to be almost undrinkable. Yet an Indian so thirsty with a violent fever quenched his thirst with this cinchona bark contaminated water and was better in a day or two.
    [Show full text]
  • A Systematic Review and Meta-Analysis on Chloroquine And
    www.nature.com/scientificreports OPEN A systematic review and meta‑analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID‑19 treatment Ramy Mohamed Ghazy1, Abdallah Almaghraby2*, Ramy Shaaban3, Ahmed Kamal4, Hatem Beshir5,6, Amr Moursi7, Ahmed Ramadan8 & Sarah Hamed N. Taha9 Many recent studies have investigated the role of either Chloroquine (CQ) or Hydroxychloroquine (HCQ) alone or in combination with azithromycin (AZM) in the management of the emerging coronavirus. This systematic review and meta‑analysis of either published or preprint observational studies or randomized control trials (RCT) aimed to assess mortality rate, duration of hospital stay, need for mechanical ventilation (MV), virologic cure rate (VQR), time to a negative viral polymerase chain reaction (PCR), radiological progression, experiencing drug side efects, and clinical worsening. A search of the online database through June 2020 was performed and examined the reference lists of pertinent articles for in‑vivo studies only. Pooled relative risks (RRs), standard mean diferences of 95% confdence intervals (CIs) were calculated with the random‑efects model. Mortality was not diferent between the standard care (SC) and HCQ groups (RR = 0.99, 95% CI 0.61–1.59, I2 = 82%), meta‑regression analysis proved that mortality was signifcantly diferent across the studies from diferent countries. However, mortality among the HCQ + AZM was signifcantly higher than among the SC (RR = 1.8, 95% CI 1.19–2.27, I2 = 70%). The duration of hospital stay in days was shorter in the SC in comparison with the HCQ group (standard mean diference = 0.57, 95% CI 0.20–0.94, I2 = 92%), or the HCQ + AZM (standard mean diference = 0.77, 95% CI 0.46–1.08, I2 = 81).
    [Show full text]
  • Patterns of Proinflammatory Cytokines and Inhibitors During Typhoid Fever
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by RERO DOC Digital Library 1306 Patterns of Proinflammatory Cytokines and Inhibitors during Typhoid Fever Monique Keuter, Edi Dharmana, M. Hussein Gasem, University Hospital, Nijmegen. Netherlands; Diponegoro University, Johanna van der Ven-Jongekrijg, Semarang. Indonesia; F. Hoffman-Lakoche, Basel, Switzerland Robert Djokomoeljanto, Wil M. V. Dolmans, Pierre Demacker, Robert Sauerwein, Harald Gallati, and Jos W. M. van der Meer Cytokines and inhibitors in plasma were measured in 44 patients with typhoid fever. Ex vivo production of the cytokines was analyzed in a whole blood culture system with and without lipopolysaccharide (LPS). Acute phase circulating concentrations of cytokines (±SD) were as follows: interleukin (IL)-IP, <140 pg/ml.; tumor necrosis factor-a (TNFa), 130 ± 50 pg/mL; IL-6, 96 ± 131 pg/ml.; and IL-8, 278 ± 293 pg/ml., Circulating inhibitors were elevated in the acute phase: IL-l receptor antagonist (IL-IRA) was 2304 ± 1427 pg/ml, and soluble TNF receptors 55 and 75 were 4973 ± 2644 pgJmL and 22,865 ± 15,143 pgJmL, respectively. LPS­ stimulated production of cytokines was lower during the acute phase than during convalescence (mean values: IL-IP, 2547 vs. 6576 pg/ml.; TNFa, 2609 vs. 6338 pg/rnl.; IL-6, 2416 vs. 7713 pg/ml.), LPS-stimulated production orIL-iRA was higher in the acute than during the convales­ cent phase (5608 vs. 3977 pg/mL). Inhibited production of cytokines during the acute phase may bedue to a switch from a proinflammatory to an antiinflammatory mode. Typhoid fever is caused by the facultative intracellular tibodies to this cytokine are detrimental [11-16], In experi­ gram-negative bacillus Salmonella typhi and occasionally by mental Salmonella typhimurium infection in mice.
    [Show full text]
  • How I Manage the Febrile Returning Traveller*
    Proc. R. Coll. Physicians Edinb. 1998; 28: 24-33 HOW I MANAGE THE FEBRILE RETURNING TRAVELLER* D. Nathwani,† Dundee Teaching Hospitals NHS Trust, DD3 8EA Humanity has but three great enemies: fever, famine and war; of these by far the greatest, by far the most terrible, is fever. Sir William Osler Throughout the centuries, the clinical diagnosis has been made or strongly suggested by the history, the presence of helpful physical findings and the observation of the patient. Like Osler, physicians since antiquity have viewed fever, an important clinical finding, as an entity worthy of unremitting attention. An eighteenth century English diarist (Fanny Gurney, Celia Book IV, 1782) wrote that ‘travelling is the ruin of all happiness’. Fortunately, this rather gloomy outlook is no longer widely held, as illustrated by the massive increase in public spending on travel and escalation in air travel by UK residents. Between 1991 and 1995 there was a rise to 22.9 million UK residents travelling abroad (International Passenger Survey, Office for National Statistics) and a 12.5 million rise in visitors to the UK over a similar period. Although Spain and France remain the most popular destinations, increasing numbers of British people (approximately three million in 1996) are travelling to the tropics and subtropics. Fever is an important and common presentation of tropical disease and sometimes may be the only manifestation of serious illness. Indeed, 81% of travellers complaining of fever admitted to the Hospital for Tropical Diseases in London, in a period of six months had travelled to the tropics or subtropics (60% sub-Saharan Africa; 13% Indian sub-continent 8% South-East Asia).1 This suggests that both primary and secondary care physicians need to be familiar with the management of patients arriving at, or returning to, this country with a febrile illness.
    [Show full text]
  • Empirical Antibiotic Guidelines for the Management of Common Infections in Adult Inpatients
    EMPIRICAL ANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMON INFECTIONS IN ADULT INPATIENTS Useful contacts: Consultant Clinical Microbiologist via switchboard Antimicrobial Pharmacist Bleep 294 Medicines Information Ext 2092 Topic/ Heading: Empirical antibiotic guideline for the management of common infections in adult inpatients Lead Clinician for Guideline: Dr. S N Patel, Consultant Microbiologist & Nicola Robinson, Senior Pharmacist Antimicrobials/ ICU Discipline: Medicines Management / Microbiology / Pharmacy Date of Guideline: September 2017 Version: 4.0 Approved By: Drugs & Therapeutics Committee and Antibiotic Stewardship Group Date: 26/7/16 Audit Date: Monthly and as indicated in annual antibiotic audit plan Guideline Review Date: September 2018 Review Completed By: Dr. S N Patel Consultant Microbiologist, Emma Guthrie Senior Pharmacist, Agnieszka Fryer Senior Pharmacist. Rationale for Development: To support prudent use of antimicrobials across the Trust Aims and Objectives: To ensure appropriate antibiotic treatment of common infections in adult inpatients Method of Guideline Development: In accordance with Trust policy Equality Impact Assessment: n/a Roles & Responsibilities: refer to Antimicrobial Prescribing policy in PIMS Guideline: Empirical antibiotic guidelines for the management of common infections in adult inpatients Evidence Base: See reference list Consultation: 2013 Blue Book with changes approved by relevant clinicians Implementation: Available via PIMS Monitoring: Antibiotic Stewardship Group annual audit plan
    [Show full text]
  • Overview of Fever of Unknown Origin in Adult and Paediatric Patients L
    Overview of fever of unknown origin in adult and paediatric patients L. Attard1, M. Tadolini1, D.U. De Rose2, M. Cattalini2 1Infectious Diseases Unit, Department ABSTRACT been proposed, including removing the of Medical and Surgical Sciences, Alma Fever of unknown origin (FUO) can requirement for in-hospital evaluation Mater Studiorum University of Bologna; be caused by a wide group of dis- due to an increased sophistication of 2Paediatric Clinic, University of Brescia eases, and can include both benign outpatient evaluation. Expansion of the and ASST Spedali Civili di Brescia, Italy. and serious conditions. Since the first definition has also been suggested to Luciano Attard, MD definition of FUO in the early 1960s, include sub-categories of FUO. In par- Marina Tadolini, MD Domenico Umberto De Rose, MD several updates to the definition, di- ticular, in 1991 Durak and Street re-de- Marco Cattalini, MD agnostic and therapeutic approaches fined FUO into four categories: classic Please address correspondence to: have been proposed. This review out- FUO; nosocomial FUO; neutropenic Marina Tadolini, MD, lines a case report of an elderly Ital- FUO; and human immunodeficiency Via Massarenti 11, ian male patient with high fever and virus (HIV)-associated FUO, and pro- 40138 Bologna, Italy. migrating arthralgia who underwent posed three outpatient visits and re- E-mail: [email protected] many procedures and treatments before lated investigations as an alternative to Received on November 27, 2017, accepted a final diagnosis of Adult-onset Still’s “1 week of hospitalisation” (5). on December, 7, 2017. disease was achieved. This case report In 1997, Arnow and Flaherty updated Clin Exp Rheumatol 2018; 36 (Suppl.
    [Show full text]